Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined With JS001 in Advanced Solid Tumors
NCT03879057Phase 1Unknown
- Sponsor
- Peking University
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of surufatinib in solid tumor (2 arms), sponsored by Peking University. Primary endpoints: Adverse Events at 1 year and Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
surufatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03879057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879057.